ABBV Options Signal Consolidation at $255 as Wall Street Eyes $290 Target

• ABBV pulls back 2.1% to $245.66 despite strong Q2 earnings beat
• Heavy Put OI at $180 ($1,897 contracts) sets a clear downside floor
• Call wall builds at $255-$265 for this Friday’s expiration
• Analysts raise targets to $290, viewing dip as accumulation zone

The market is whispering, not shouting. AbbVie (NYSE: ABBV) has slipped to $245.66 today, a modest 2.1% drop that feels more like a breath than a collapse. While the stock is testing support, the options chain tells a different story. We aren't seeing panic. We're seeing structure. The data suggests that while short-term traders are cautious, the broader market is positioning for a range-bound consolidation before the next leg up. The tension here is palpable: fundamentals are strong, but technicals are whispering "wait." Let’s break down what’s actually happening under the hood.

The $180 Put Wall and the $255 Call Magnet

When you look at the open interest distribution, the story is one of defined boundaries. For this Friday’s expiration, the most significant put concentration sits at the $180 strike with an open interest of 1,032 contracts, but the real anchor is the $180 strike for next Friday’s expiry with a massive 1,897 contracts. This isn't noise; this is a floor. Market makers and institutional players are heavily hedging downside risk around the $180 level, which is far below current prices but acts as a psychological and technical safety net for long-term holders.

On the upside, the call side is interesting. This Friday, we see a cluster of OTM calls at $255 (OI: 397) and $257.5 (OI: 412). Next Friday, the $255 strike also holds 140 contracts. This suggests that near-term traders expect the stock to bounce off current lows but struggle to break significantly above $257.5 in the immediate term. The Put/Call ratio for open interest sits at 0.84, which leans slightly bullish, indicating that for every dollar of put protection, there’s more capital flowing into calls. However, the absence of significant whale block trades today suggests this move is organic retail and algorithmic trading, not institutional dumping.

Earnings Beat Meets Acquisition Anxiety

The news flow is a mixed bag that explains the current hesitation. AbbVie reported robust Q2 2026 earnings, beating revenue expectations with $16.99 billion and raising adjusted EPS to $3.65. That’s strong. But the market punished the stock because of the Apogee Therapeutics acquisition. The $10.9 billion deal brings dilution of $0.14 per share, causing management to lower full-year EPS guidance to $13.87–$14.07.

This is where perception clashes with reality. Wall Street firms like Canaccord Genuity, JPMorgan, and Morgan Stanley have raised their price targets to $290, $285, and $296 respectively. They see the Apogee deal not as a cost, but as a pipeline booster for Skyrizi and Rinvoq, which grew 24% each. The current pullback is essentially the market digesting the short-term dilution against the long-term $5 billion potential of Apogee’s zumilokibart. The sentiment is cautious optimism: "Buy the dip, but keep your stop-losses tight."

Trading the Range: Entry Points and Option Plays

So, how do we trade this? The technicals show a short-term bearish trend with RSI at 53.05, hovering near the middle of the Bollinger Bands. The 30-day moving average is at $250.25, which acts as immediate resistance. Here is a concrete plan:

• Stock Entry: Consider accumulating shares near $244.88 (today’s low) if the price holds. A confirmed break above $250.25 (30-day MA) would signal a shift back to bullish momentum, with a target near $256.20 (today’s high).
• Option Strategy 1 (Bullish Call Spread): For those betting on a bounce this Friday, look at ABBV20260807C255. It has decent open interest (397) and is slightly out of the money. Pairing this with a ABBV20260807C262.5 (OI: 1,091) creates a credit or debit spread that caps risk while capturing upside if the stock reclaims $255.
• Option Strategy 2 (Hedging for Next Week): Given the heavy put OI at $180 for next Friday, buying ABBV20260814P180 is an expensive but effective hedge against a black swan event. For a more balanced view, consider buying ABBV20260814C265 (OI: 860). This strike aligns with the upper bound of the current Bollinger Band ($264.26) and offers leverage if the analyst consensus of $290 starts to materialize in the next two weeks.

Volatility on the Horizon

The setup for AbbVie is classic accumulation. The strong fundamentals and analyst upgrades provide a high floor, while the options market has built a cage around $245–$255. The key is patience. The stock is unlikely to explode vertically today, but the downward momentum appears exhausted. If you’re holding, this is a good time to sit tight. If you’re looking to enter, let the $250 resistance break before chasing the price. The $290 target isn't a fantasy; it’s a consensus waiting for the right catalyst. Keep your eyes on the $255 call wall—if it breaks, the path to $265 opens wide.